Cannabidiol Inhibits <i>In Vitro</i> Human Liver Microsomal Metabolism of Remdesivir

Saraswat, Aishwarya; Vartak, Richa; Patki, Manali; Patel, Ketan

doi:10.1089/can.2021.0109

Cited by 4 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, following in vitro study results suggesting the potential activity of CBD in reducing coronavirus replication and virus-induced cytokine release [ 10 , 42 ], CBD was recently approved by FDA for a clinical trial to treat lung inflammation induced by COVID-19 [ 43 ] (Clinical trial identifier: NCT04686539, NCT04731116). In addition to our present evaluation, recent research from another group using microsomal incubations demonstrated that CBD inhibited RDV hydrolysis [ 44 ]. The potential DDI between CBD and the COVID-19 therapeutic agent RDV should be appreciated by clinicians using the antiviral.…”

Section: Discussionmentioning

confidence: 83%

In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir

Zhang¹,

Melchert²,

Markowitz

2022

Chemico-Biological Interactions

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 83%

In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir

Zhang¹,

Melchert²,

Markowitz

2022

Chemico-Biological Interactions

View full text Add to dashboard Cite

“…On the other hand, CBD is capable of significantly inhibiting the human hepatic microsomal metabolism of Remdesivir (RDV), the first drug for viral therapy to treat SARS-CoV2/MERS-CoV infection, extending the half-life of RVD through the remarkable inhibitory activity of human liver carboxylesterase-1 (CES1) and CYP3A4 microsomal metabolism. These findings suggest that CBD could be an adjuvant to RDV in the treatment of SARS-CoV2 infection [109].…”

Section: Indispensable Proteins For the Development Of Infection And Cbdmentioning

confidence: 84%

Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment

Pérez

Glaser

Villegas

et al. 2022

Life

View full text Add to dashboard Cite

Cannabis sativa is one of the first medicinal plants used by humans. Its medical use remains controversial because it is a psychotropic drug whose use has been banned. Recently, however, some countries have approved its use, including for recreational and medical purposes, and have allowed the scientific study of its compounds. Cannabis is characterized by the production of special types of natural products called phytocannabinoids that are synthesized exclusively by this genus. Phytocannabinoids and endocannabinoids are chemically different, but both pharmacologically modulate CB1, CB2, GRP55, GRP119 and TRPV1 receptor activities, involving activities such as memory, sleep, mood, appetite and motor regulation, pain sensation, neuroinflammation, neurogenesis and apoptosis. Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are phytocannabinoids with greater pharmacological potential, including anti-inflammatory, neuroprotective and anticonvulsant activities. Cannabidiol is showing promising results for the treatment of COVID-19, due to its capability of acting on the unleashed cytokine storm, on the proteins necessary for both virus entry and replication and on the neurological consequences of patients who have been infected by the virus. Here, we summarize the latest knowledge regarding the advantages of using cannabinoids in the treatment of COVID-19.

show abstract

“…Among COVID-19 patients, the use of CBD can be beneficial against the cytokine release syndrome but should be proved by clinical trials. CBD has been recently considered as a possible drug in the treatment of SARS-CoV-2 ( 41 – 43 ). This molecule can decrease the release of proinflammatory cytokines responsible for inflammation during SARS-CoV-2 infection ( 4 ).…”

Section: Cbd and The Cytokine Storm In Sars-cov-2 Infectionmentioning

confidence: 99%

Cannabidiol and SARS-CoV-2 Infection

Vallée

2022

Front. Immunol.

View full text Add to dashboard Cite

Cannabidiol (CBD) can prevent the inflammatory response of SARS-CoV-2 spike protein in Caco-2-cells. This action is coupled with the inhibition of IL-1beta, IL-6, IL-18, and TNF-alpha, responsible for the inflammatory process during SARS-CoV-2 infection. CBD can act on the different proteins encoded by SARS-CoV-2 and as an antiviral agent to prevent the viral infection. Furthermore, recent studies have shown the possible action of CBD as an antagonist of cytokine release syndromes. In the SARS-CoV-2 pathophysiology, the angiotensin-converting enzyme 2 (ACE2) seems to be the key cell receptor for SARS-CoV-2 infection. The WNT/β-catenin pathway and PPARγ interact in an opposite manner in many diseases, including SARS-CoV-2 infection. CBD exerts its activity through the interaction with PPARγ in SARS-CoV-2 infection. Thus, we can hypothesize that CBD may counteract the inflammatory process of SARS-CoV-2 by its interactions with both ACE2 and the interplay between the WNT/β-catenin pathway and PPARγ. Vaccines are the only way to prevent COVID-19, but it appears important to find therapeutic complements to treat patients already affected by SARS-CoV-2 infection. The possible role of CBD should be investigated by clinical trials to show its effectiveness.

show abstract

Cannabidiol Inhibits In Vitro Human Liver Microsomal Metabolism of Remdesivir

Cited by 4 publications

References 41 publications

In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir

In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir

Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment

Cannabidiol and SARS-CoV-2 Infection

Contact Info

Product

Resources

About